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to elicit preference values for HCV-specific health states from general public par-
ticipants in Australia, Brazil, France, Italy, and Spain. METHODS: HCV health state 
descriptions were based on literature review and clinical expert feedback for the 
following: asymptomatic and symptomatic mild/moderate HCV, compensated cir-
rhosis, five decompensated cirrhosis states (hepatocellular carcinoma, ascites, acute 
and chronic variceal hemorrhage, and hepatic encephalopathy), and liver transplant 
(first year and subsequent years). These descriptions included key HRQoL impacts 
(activities, mood, stigma, cognition, and sleep) associated with each state, and were 
validated by members of the general public. Trained interviewers elicited time 
trade-off preference values (or, utilities) from a general public sample, quantifying 
preferences for each health state on a scale of 0 (dead) to 1 (full health). Mean (95% 
confidence interval) preferences were estimated for each country and adjusted for 
age and sex using beta and generalized linear models. RESULTS: Logical responses 
from 488 participants were included; approximately 50% were male. Mean ages 
ranged from 39.1 (Brazil) to 47.7 (Italy) years. Mean values for asymptomatic mild/
moderate HCV health states ranged from 0.90 (0.88-0.91; Australia) to 0.79 (0.76-
0.81; Brazil); for the acute variceal hemorrhage health state, mean values were 
0.27 (0.24-0.29; France) to 0.39 (0.39-0.42; Italy). Mean preferences for compensated 
cirrhosis ranged from 0.69 (0.33-0.72; Brazil) to 0.77 (0.75-0.79; Australia). Values 
were less than 0.70 for all decompensated cirrhosis states. Age- and sex-adjusted 
beta and generalized linear models showed similar results. CONCLUSIONS: This 
study provides estimates of the quality of life decrement associated with severe 
liver disease health states, from the general public perspective. This information 
is important for understanding the benefit of early treatment to delay disease pro-
gression in patients with HCV.
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OBJECTIVES: Standardized methods to measure symptoms and related patient-
reported outcomes (PRO) in Hospital-Acquired Bacterial Pneumonia (HABP) are 
limited. The purpose of this literature review was to identify signs, symptoms, and 
measurement tools associated with patients’ experience of HABP. The results will 
be used to inform the development of a valid PRO tool for HABP that is consistent 
with the FDA PRO Guidance. METHODS: To identify relevant literature, MEDLINE 
(1946 to 2014) and EMBASE (1988 to 2014) databases were searched individually 
and in combination using terms related to Hospital-Acquired Pneumonia (HAP), 
HABP, signs and symptoms, and patient-reported outcomes. RESULTS: The search 
identified 1384 abstracts. 225 were excluded as duplicates or for missing content. 
1145 abstracts were excluded based on pre-specified criteria. The remaining articles 
were scrutinized for eligibility, resulting in six that met the inclusion criteria. The 
most frequently cited signs and symptoms of HABP were fever, cough, purulent spu-
tum, dyspnea, rales, chest pain, and elevated respiratory rate. No PRO measures for 
assessing HABP signs and symptoms were identified in the literature. Current HABP 
clinical trials have not included end points that directly measure how a patient 
feels and functions. CONCLUSIONS: The HABP literature has historically focused 
on clinical outcomes to evaluate treatment efficacy and there is currently limited 
evidence assessing the impact of antibiotic therapies on symptomatology in HABP 
patients. Endpoints, such as clinical response, clinical cure, and time to event, are 
only indirect measures of treatment benefit and have not been validated. It is essen-
tial to develop reliable, well-defined and clinically relevant endpoints that measure 
tangible benefits for patients in clinical trials of antibacterial drugs in accordance 
with the FDA Guidance for PRO measures and HABP. This literature review is the first 
step in identifying concepts that will be explored further in qualitative interviews 
with HABP patients.
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OBJECTIVES: Pegylated-interferon/ribavirin (PR) is commonly used to treat HCV 
genotype 1 (G1) -infected patients, both as dual therapy or triple therapy, combined 
with a direct-acting antiviral (DAA). PR-based treatments are associated with high 
levels of toxicity and decreased QoL. Adding simeprevir as DAA to PR reduces dura-
tion of PR-therapy and increases significantly the proportion of patients reaching 
viral response (VR). The objective of this analysis was to explore the impact of dura-
tion of PR therapy and of having VR on the level of impairment of QOL and other 
patient-reported outcomes (PRO). METHODS: Longitudinal QoL/PRO outcomes were 
analyzed from three randomized clinical trials comparing PR+simeprevir with PR 
in treatment-naïve HCV-G1 patients: PILLAR (n= 316); QUEST-1 (n= 394) ; QUEST-2 
(n= 391). Early responders in the simeprevir arm were allowed to stop PR-therapy at 
24 weeks, instead of 48 week PR-therapy. A mixed-effects model was fitted, including 
age, gender, baseline fibrosis status, time, treatment interaction between time and 
treatment as covariates, and PR-therapy and viral response as binary time-varying 
covariates (viral load < /≥ 25 IU/ml). A model was fitted by trial for the EQ-5D valu-
ation index (VI) and visual analog scale (VAS), the Fatigue Symptom Severity scale 
(FSS) and the Center for Epidemiologic Studies Depression Scale (CES-D). RESULTS: 
Shortened PR-therapy positively impacted all PRO-endpoints consistently across all 
studies (p-values ranging between < 0.0001 and 0.025). The estimated mean for the 
positive impact on EQ5D-VI were 0.08 (p= 0.0001), 0.05 (p= 0.025) and 0.08 (p= 0.0005) 
this population. Results also suggest that the knowledge gap is greater among males 
than females. This in mind, PPPP includes culturally sensitive elements such as a 
skit developed by community members and small group discussions to engage the 
population in conversations about pneumonia.
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OBJECTIVES: The purpose of this study was to develop a patient-reported out-
come (PRO) instrument to assess Acute Bacterial Skin and Skin Structure Infection 
(ABSSSI) symptoms in patients in clinical trials of antibacterial drugs, consistent 
with FDA PRO Guidance. METHODS: A comprehensive review of the literature and 
interviews with nine US and European clinical experts informed the development 
of a concept elicitation (CE) interview guide, and a hypothetical conceptual frame-
work and disease model exploring patients’ experience with symptoms of ABSSSI. 
CE was based on telephone interviews with 34 patients, after which saturation 
of emergent concepts was reached. Items and response options were generated 
based on the qualitative data and a draft instrument was prepared with input and 
review from an international project team of academic and industry antibacte-
rial experts. Subsequently, cognitive debriefing interviews were conducted with 15 
ABSSSI patients and 3 clinical experts to assess item readability, relevance, com-
prehensiveness, and content validity. Items were edited based on feedback from 
the patients. RESULTS: CE subtypes were evaluated and consisted of 13 (38.2%) 
patients with major abscess, 12 (35.3%) with wound infection, and 9 (26.5%) with 
cellulitis. In terms of severity, the majority (79.4%) of infections were rated as moder-
ate by clinicians. The mean age of patients was 38.8 years; 64.7% male. Symptoms 
were common across all ABSSSI subtypes and supported the saturation of con-
cepts. Items were generated for the PRO Instrument using patient terminology. 
Subsequent cognitive debriefing with patients demonstrated that the items were 
understandable, relevant, and interpreted as intended. CONCLUSIONS: SKINFECT is 
a PRO instrument developed to evaluate ABSSSI patient symptoms and functioning 
in clinical studies with documented evidence of content validity. Qualitative data 
from patients and input from experts formed the basis of the SKINFECT’s structure 
and item pool, and it is now ready for psychometric reliability and validity testing.
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OBJECTIVES: There is a paucity of evidence regarding a well-defined, reliable, and 
feasible method for measuring efficacy outcomes from a patient perspective in 
Community-Acquired Bacterial Pneumonia (CABP) trials. Most CABP studies eval-
uate treatment efficacy on the basis of clinical outcomes; however, there is no 
patient-reported outcome (PRO) to capture additional symptoms of how patients 
feel, function, or survive. The goal of this study was to explore CABP symptoms as 
reported by patients, and to develop a draft PRO instrument designed to compre-
hensively assess these symptoms. METHODS: Concept elicitation was conducted by 
telephone interviews with patients within 10 days of CABP diagnosis. Data was ana-
lyzed using an iterative process to identify themes and concepts and was recorded 
in a saturation grid. Saturation was monitored according to the FDA PRO guidance. 
Using this qualitative data, a draft PRO instrument was prepared. Cognitive debrief-
ing interviews were conducted to assess item readability, relevance, comprehen-
siveness, and content validity. RESULTS: Twenty patients participated in concept 
elicitation interviews. Mean age of the patients was 59.5 years (SD = 18.8, range: 
29-90); 45% were female. The most common symptoms reported included a lack of 
energy or tiredness (n= 18), cough (n= 16), and shortness of breath (n= 16). Nearly 
half the patients also reported fever, chest pain and general aches/pain as well as 
significant impacts on their social (n= 10) and physical functioning (n= 17) related 
to the skin infection. Subsequent cognitive debriefing in 9 patients and 3 clinical 
experts demonstrated that the items were understandable, relevant, and interpreted 
as intended. CONCLUSIONS: Qualitative data from patients and input from experts 
formed the basis of the CABP PRO structure and item pool. These patient-reported 
CABP symptoms were shown to demonstrate content saturation and concept valid-
ity and provide unique information important for both comprehensive evaluation 
of individuals with CABP and evaluation of new antibacterial treatments.
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OBJECTIVES: Limited country-specific data exist on health-related quality-of-life 
(HRQoL) impacts of hepatitis C virus (HCV) infection. The aim of this study was 
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2014, 251 EU5 gastroenterologists were surveyed regarding their perceptions and 
uptake of sofosbuvir. Additionally, 15 reimbursement-influencing payers were 
interviewed. RESULTS: At the time of surveying, approximately one-quarter of 
treatment-naïve cirrhotic and non-cirrhotic HCV-1 patients in France and Germany 
(where sofosbuvir was then widely available) were on sofosbuvir-based regimens, 
alongside a slightly lower percentage of treatment-experienced such patients, and 
those with HCV-2/3. This speedy uptake reflects sofosbuvir’s high efficacy, which 
previously encouraged physician familiarity via early-access schemes. However, 
interviewed payers insist sustained uptake for large HCV patient populations is 
not viable due to cost, stressing that sofosbuvir be reserved for patients with more 
advanced liver fibrosis or cirrhosis. These payers add that measures such as those 
in France involving treatment caps and a proposal to tax manufacturers when caps 
are exceeded exemplify the innovative cost-containment strategies necessary to 
manage the burden of sofosbuvir. CONCLUSIONS: The EU5 healthcare authorities 
have adapted to include sofosbuvir within their budgets. As indicated by our primary 
research, and confirmed since, creative cost-containment is the order of the day 
across the EU5 for sofosbuvir, with payers forced to reexamine their traditional P&R 
schemes and reevaluate how they define cost-effectiveness. However, such aggres-
sive cost-containment measures have consequences, as demonstrated when thou-
sands took to the streets in Spain in January, 2015, protesting for fairer allocation 
of HCV treatment. Manufacturers of such premium-priced agents may learn from 
Janssen’s negotiations on simeprevir, which offered trade-offs using teleprevir, as 
careful balancing of long-range price expectations and reimbursement and uptake 
potential will be required going forward.
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OBJECTIVES: Misbeliefs regarding vaccine safety and strict immunization exemp-
tion policy have led to anti-vaccination sentiments in West Virginia which might 
affect the vaccination of children. This study assessed the levels of worry and 
hassles towards vaccination and their association with up-to-date vaccination 
status and future intentions to follow recommended vaccinations. METHODS: A 
cross-sectional online survey was conducted among 176 mothers of children under 
3 years old in West Virginia who could read and understand English. Worry and 
hassles scales were developed, and mean scale scores were used to measure worry 
and hassles to vaccination. Chi-square, t-tests and logistic regression analyses 
were conducted. RESULTS: Participants were predominantly white (94.3%), non-
Hispanic Appalachians (98.3%), with annual household income > $50,000 (72.6%) 
and health insurance (92.0%). Approximately 3.8% of participants’ children had not 
received any vaccination. Further, many participants’ children (14.2%) were not up 
to date with recommended vaccinations, and 13.6% of mothers reported no future 
intention to follow recommended vaccination. Chi-square analyses indicated that 
being a full time worker and self or family as child caretaker were associated with 
being up-to-date with recommended vaccination and future intention to follow 
recommended vaccinations (p’s< 0.05). After adjusting for demographic variables, 
hassle scale was a significant predictor of up-to-date vaccination status (AOR 
= 0.12) and future intention to follow recommended vaccinations (AOR = 0.17). 
Similarly, worry scale was a significant predictor of up-to-date vaccination status 
(AOR = 0.24) and future intention to follow recommended vaccinations (AOR = 
0.27). CONCLUSIONS: Despite having higher socio-economic status, many study 
participants’ children exhibited low immunization coverage, and had no future 
intention to follow recommended vaccination. The study highlights the need to 
increase awareness about safety of vaccine contents and its efficacy in preventing 
still endemic diseases like measles.
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OBJECTIVES: The current Ebola Virus outbreak has been responsible for over 5,000 
deaths. This disease, with no effective treatment has a fatality rate around 50%. 
In October, the EMA publically encouraged developers of Ebola treatments and 
vaccines to apply for orphan designation and FDA have already granted orphan 
designation for ZMapp. This research aimed to evaluate the appropriateness of 
utilising the orphan designation as an incentive in these circumstances or whether 
it could actually prove counter-productive. METHODS: A detailed review of EMA and 
FDA orphan designation procedures and the historical context in which they were 
developed were undertaken, alongside a review of the current Ebola treatment and 
vaccinations pipeline. RESULTS: EMA and FDA orphan drug legislation comprise a 
set of incentives for pharmaceutical companies to develop and market medicinal 
products to treat rare diseases, which were being neglected by drug developers due 
to the poor economic potential of such diseases. These include scientific advice, 
fee reductions, access to grants and, most importantly, market exclusivity (7 and 
10 years for the FDA and EMA respectively). However, in contrast to most orphan 
diseases with a lack of pipeline candidates, there are already 7 pipeline drugs for 
Ebola (brincidofovir, favipiravir, ZMapp, TKM-Ebola, AVI-4753, hyperimmune horse 
sera, and BCX4430) and 2 vaccines (ChAd 3, VSV-EBOV). CONCLUSIONS: Granting 
orphan status to pipeline Ebola candidates means that the first-to-market will attain 
market exclusivity in that jurisdiction, such that any later candidates, even if clearly 
more effective, will be prevented from launching until the data exclusivity period 
has expired. This could not only potentially deny Ebola patients in US and Europe 
access to the most efficacious treatments but could also disincentivize companies 
developing potentially more effective therapies. We recommend that the market 
exclusivity aspect of the orphan drug designation should be waived for candidate 
Ebola treatments.
for PILLAR, QUEST-1 and QUEST-2, respectively. Having VR only had a minor posi-
tive impact, and was not statistically significant for most endpoints/trials. Female 
patients had significantly lower values for EQ-5D-VI, and numerically lower values 
for all other QoL-measures. CONCLUSIONS: These findings suggest that short-
term QoL impairment due to HCV-therapy is driven more by the longer duration of 
PR-therapy than by not obtaining VR.
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OBJECTIVES: Limited Patient Reported Outcomes (PRO) data exists for obese 
patients with ABSSSI. This study sought to evaluate health-related quality of life 
(HRQL) in obese patients (BMI > 30) with a positive clinical response (cured, com-
plete resolution of all baseline signs and symptoms and improved, some symp-
toms remain, but no further antibiotics are necessary) patients during an ABSSSI 
trial. METHODS: Adult patients diagnosed with ABSSSI were enrolled in a pro-
spective phase 3, randomized, double-blind study to evaluate antibiotic treatment. 
An analysis of PRO was conducted to understand the difference between cured 
obese patients (COP) and improved obese patients (IOP) with respect to patient 
reported HRQL at End of Treatment (EOT) and late follow up (LFU, study day 21-28). 
HRQL was measured by Extremity Soft Tissue Infection (ESTI) Score[i], a 20 ques-
tion survey using a 5-point Likert scale (5 equals highest degree of importance/
impairment to the patients) measured symptoms, daily functioning, emotional 
functioning, and social interactions. RESULTS: Obese patients compromised 29% 
of the study (660 patients, 589 included in analysis, 193 obese). IOP at EOT were 
less likely to proceed to cure than non-obese patients (26%, 16%) at LFU. The ESTI 
Score was higher at LFU in IOP than COP (46.4, 26.3, p= 0.029). At LFU, IOP were 
more likely than COP to report having continued difficulty performing a job (29.0%, 
9.6%, p= 0.008) and earning an income (32.3%, 14.0%, p= 0.032). CONCLUSIONS: IOP 
had more difficulty than COP with HRQL measures at LFU. IOP at EOT may have 
persistent HRQL issues that require further utilization of health care resources. 
Additional research is needed to determine the potential economic impact of this 
data. [i] Storck et al, Development of a Health-Related Quality of Life Questionnaire 
(HRQL) for patients with Extremity Soft Tissue Infections (ESTI), BMC Infectious 
Diseases 2006, 6:148
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OBJECTIVES: The FDA plans to institute a novel regulatory pathway to expedite 
approval of high-need antibiotics, including those for multidrug-resistant gram-
negative pathogens (MDR GNPs). Under this Limited Population Antibacterial Drugs 
(LPAD) approval mechanism, submission of clinical efficacy data from relatively 
small patient populations with high unmet need would be permitted. However, 
drugs approved via this pathway will have limited safety data and likely carry sig-
nificant price premiums over standard-of-care. This study assessed potential mar-
ket access hurdles for LPAD pathway-approved agents providing improvements in 
clinical cure rates, mortality rates and/or length of hospital/ICU stay for infections 
caused by MDR GNPs. METHODS: A total of 30 U.S. hospital pharmacy directors (PDs) 
and 141 U.S hospital-based infectious disease (ID) and non-ID specialists were sur-
veyed regarding their views on reimbursement and likely uptake of LPAD pathway-
approved drugs, assuming these agents cost ≥ $15,000/treatment course. RESULTS: 
Among surveyed physicians and PDs, < 25% and < 50%, respectively, were aware of 
the proposed LPAD pathway. Based on a short explanation, 87% of surveyed PDs 
would include LPAD pathway-approved agents. Among these PDs, 96% would imple-
ment prescribing restrictions on top of those included in the product label, although 
only 27% indicated they would restrict these agents to last-line therapy. Among 
physician respondents, 84% reported that they would use formulary-included LPAD 
pathway-approved agents providing improvements over standard-of-care, with 
agents demonstrating lower mortality rates relative to comparators more likely to 
see uptake. Furthermore, surveyed physicians who would use an LPAD pathway-
approved agent are most likely to do so for the same infections and drug-resistant 
pathogens evaluated during the LPAD process. CONCLUSIONS: Physicians and pay-
ers are receptive to LPAD pathway-approved agents despite potential for safety risks 
and high price premiums. However, prescribing restrictions and price limitations 
are certain among payers, while primary prescribing drivers are improvements in 
clinical cure and mortality rates.
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OBJECTIVES: Sofosbuvir is an indispensable innovation in hepatitis C virus (HCV) 
treatment. However, it has the potential to bust tight EU5 healthcare budgets. 
This study examined early uptake of sofosbuvir, and explored evolving mecha-
nisms in the EU5 used to manage its high cost burden. METHODS: In September 
